497 results on '"Tsimikas, Sotirios"'
Search Results
2. Oxidized Phospholipids and Calcific Aortic Valvular Disease
3. Human circulating CD24hi marginal zone B cells produce IgM targeting atherogenic antigens and confer protection from vascular disease
4. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis
5. Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease
6. On-treatment platelet reactivity through the thromboxane A2 or P2Y12 platelet receptor pathways is not affected by pelacarsen
7. Atherothrombotic and thrombolytic biomarkers in incident stroke and atrial fibrillation-related stroke: The Multi-Ethnic Study of Atherosclerosis (MESA)
8. Increased LL37 in psoriasis and other inflammatory disorders promotes LDL uptake and atherosclerosis
9. Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease
10. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests
11. Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study
12. Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis
13. Effects of mixed nut consumption on LDL cholesterol, lipoprotein(a), and other cardiometabolic risk factors in overweight and obese adults
14. Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: The multi-ethnic study of atherosclerosis
15. High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction
16. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial
17. Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects
18. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study
19. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia
20. Development and validation of an isoform-independent monoclonal antibody–based ELISA for measurement of lipoprotein(a)
21. Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study
22. Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis
23. Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
24. Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study
25. Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification
26. Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity
27. Lp(a), oxidized phospholipids and oxidation-specific epitopes are increased in subjects with keloid formation
28. Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies
29. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
30. Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen
31. Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a)
32. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements
33. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
34. In Search of an Accurate Measurement of LDL-C: Correction for Lp(a)-Cholesterol to Predict Clinical Outcomes.
35. Lipoprotein(a) in the Year 2024: A Look Back and a Look Ahead.
36. Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a)
37. The dedicated “Lp(a) clinic”: A concept whose time has arrived?
38. Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis
39. Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis
40. PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults
41. Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis
42. Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia
43. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
44. Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography
45. A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma
46. Lipoprotein(a), Oxidized Phospholipids, and Progression to Symptomatic Heart Failure: The CASABLANCA Study.
47. PCSK9 Activity Is Potentiated Through HDL Binding
48. Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages
49. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study
50. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.